Sagimet Biosciences Q2 net loss widens on higher R&D costs
SGMT•Analyst coverage and price target
The current average analyst rating on the shares is "buy", with 11 strong buy or buy ratings, 1 hold rating and no sell or strong sell ratings.
The average consensus recommendation for the biotechnology and medical research peer group is "buy".
Wall Street's median 12-month price target for Sagimet Biosciences Inc. is $28.00, about 192.6% above its August 10 closing price of $9.57.
Equity financing boosts cash position
The company completed $175 million in equity financing in April 2026 to support clinical development and operations.
Sagimet said its cash position of $257.6 million is expected to fund operations through 2028, including the Phase 3 denifanstat data readout.
Quarterly loss widens as R&D spending rises
Sagimet Biosciences said its second-quarter net loss widened year over year as research and development expenses increased.
The biopharmaceutical firm reported a .
